Harrop Sean, Abeyakoon Chathuri, Van Der Weyden Carrie, Prince H Miles
Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
Monash Health, Melbourne, VIC 3168, Australia.
J Pers Med. 2021 May 27;11(6):481. doi: 10.3390/jpm11060481.
The T-cell lymphomas are a rare group of Non-Hodgkin's lymphomas derived from mature T-lymphocytes. They are divided broadly into the Peripheral T-cell lymphomas and the Cutaneous T-cell lymphomas. Clinical outcomes vary widely but are generally unsatisfactory with current treatments. The development of an understanding of the various critical pathways in T-cell lymphogenesis and subsequent identification of therapeutic targets has led to a rapid expansion of the previously underwhelming T-cell lymphoma armament. This review aims to provide an up-to-date overview of the current state of targeted therapies in the T-cell lymphomas, including novel antibody-based treatments, small molecule inhibitors and immune-based therapies.
T细胞淋巴瘤是一组罕见的非霍奇金淋巴瘤，起源于成熟T淋巴细胞。它们大致分为外周T细胞淋巴瘤和皮肤T细胞淋巴瘤。临床结果差异很大，但目前的治疗方法总体效果不佳。对T细胞淋巴细胞生成中各种关键途径的认识发展以及随后治疗靶点的确定，导致了以前并不突出的T细胞淋巴瘤治疗手段迅速扩展。本综述旨在提供T细胞淋巴瘤靶向治疗现状的最新概述，包括新型抗体治疗、小分子抑制剂和免疫治疗。
